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TOPICAL ANTIFUNGALS 
 
 Topical antifungals are routinely used for the treatment of mild 
dermatophyte infections. Extensive dermatophytic infections and infections of 
hair and nails which affect the quality of life of people are treated with systemic 
anti fungals.  The most commonly used topical antifungal agents are  
• Allylamines 
• Imidazoles 
• Morpholines and 
• Polyenes.  
 Older medications like whitfield ointment, castellani or paint of magenta, 
gentian violet and undecyclic acid are now replaced by specific agents.  Most of 
the specific anti fungals act on the various steps involved in the synthesis of 
fungal cell membrane. 
 Advantages of topical antifungals are less cost, easy application, less 
adverse effects and less interaction with other drugs. New topical anti fungals 
are introduced in the market which show more efficacy, safety and increased 
persistence in skin for longer periods. 
 Aim of our study is to assess the efficacy, safety and tolerability of 
Sertaconazole 2%, Terbinafine 1% and Luliconazole 1% in treatment of 
superficial cutaneous mycoses (Tinea corporis)   
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SUPERFICIAL CUTANEOUS MYCOSES (TINEA CORPORIS) 
FUNGI 
                Fungi are ubiquitious and play an important role in degradation of 
organic matter. Previously they were considered as descendants of the kingdom 
of plants. But later they were classified as a different kingdom. They are both 
saprophytes and parasites. They are different from bacteria and virus based on 
certain biochemical properties like lysine synthesis. They have all the features 
of eukaryotic organisms like presence of rigid cell wall, mitochondria, 
ribosome, membrane bound nucleus and chromosomes1. 
CLASSIFICATION OF FUNGI 
Phylum 
Growth 
Form 
Hyphae 
Sexual 
Propagules 
Asexual 
Propagules 
Zygomycota Moulds Broad few septa Zygospores Sporangiospores 
Ascomycota 
Moulds 
Yeasts 
Narrow regular 
Septa 
Ascospores Conidia 
Basidiomycota 
Moulds 
Yeasts 
Narrow regular 
Septa  
clamp 
Connections 
Basidiospores Conidia 
Deuteromycota 
Moulds 
Yeasts 
Narrow regular 
Septa 
None Conidia 
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CULTURE CHARACTERISTICS AND MORPHOLOGY   
 Sabouraud’s dextrose agar (SDA) (dextrose 40 g; agar 20g; peptone 10g 
and distilled water) is the most commonly used isolation medium. 
Cycloheximide (0.5 g/L) and chloramphenicol (0.05 g/L) inhibit bacteria, 
making the medium highly selective for the isolation of dermatophytes. 
Commercial versions of this agar are Mycosel and Mycobiotic. Dermatophyte 
test medium (DTM) contains the pH indicator phenol red; it turns red when 
dermatophyte proteolytic activity increases the pH to 8 or above. Potato 
dextrose agar (PDA) stimulates the production of conidia and pigment. Finally, 
species of Trichophyton are often differentiated by their nutritional requirement, 
revealed on Trichophyton agar by numbers 1 to 7(2-10).  
Standardization of media is essential. Cultures are incubated at room 
temperature (26C/78.8F) for up to 4 weeks. With more than 40 known 
dermatophytes, proper identification requires a suitable reference source. 
Organism Colony Morphology Microscopic Appearance 
E.floccosum(11-
14) 
Flat feathery colonies with a central fold 
and yellow to dull grey-green pigment. 
Yellow to brown  on reverse pigment 
 
No microconidia, numerous 
thin and thick-walled, club-
shaped macroconidia. 
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P0oM.audouinii Flat and white to grey with widely spaced 
radial grooves. Tan to salmon reverse 
pigment. Salmon-pink pigment on PDA. 
No growth on polished rice. 
 
Terminal chlamydoconidia 
and pectinate (comb-like) 
hyphae 
M. canis Flat, white to light yellow, coarsely hairy, 
with closely spaced radial grooves. 
Yellow to orange on reverse pigment - 
Yellow on PDA. Growth on polished rice 
Few microconidia, numerous 
thick walled and echinulate 
macroconidia with terminal 
knobs. 
M. gypseum Flat and granular with tan to buff 
pigment, no reverse pigment 
 
Few microconidia, numerous 
thin walled macroconidia 
without knobs 
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T. 
mentagrophytes 
White to creamy with a cottony, mounded 
surface. Non to light brown reverse 
pigment. No pigment on PDA Urease 
positive. 
 
Clustered round microconidia, 
rare cigar-shaped 
macronconidia, occasional 
spiral hyphae. Hair 
perforation positive. 
T.rubrum Mounded white center with maroon 
periphery. Maroon reverse pigment 
Cherry red on PDA. Urease negative 
 
Few tear-shaped 
microconidia, rare pencil-
shaped macroconidia Hair 
perforation negative. 
T.schoenleinii Heaped or folded and whitish. Colorless 
to yellow-tan reverse pigment. 
 
Knobby antler-like hyphae 
(favic chandeliers), numerous 
chlamydoconidia. 
T. tonsurans Suede-like center with feathery periphery, Numerous multiform 
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white to yellow or maroon color. Reverse 
pigment usually dark maroon, sometimes 
none to yellow. Partial thiamine 
requirement. 
 
microconidia and rare cigar-
shaped macroconidia. 
T.verrucosum Small and heaped, though sometimes flat, 
white to yellow-grey. Reverse pigment 
none to yellow. Requires thiamine and 
usually inositol for growth. 
 
Chains of chlamydoconidia on 
Sabouraud dextrose agar. 
Long and thin “rat-tail” 
macroconidia with thiamine. 
T.violaceum 
Waxy and heaped, deep purplish-red. 
Purple reverse pigment. Partial thiamine 
requirement. 
Irregular hyphae with 
intercalary chlamydoconidia. 
No micro-or macroconidia on 
SDA, rare micro-and 
macroconidia with thiamine. 
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PATHOGENESIS: 
Host factors which prevent fungal infection are UV light, temperature and 
moisture, competition from normal flora, and fungistatic fatty acids and 
sphingosines produced by keratinocytes. . After adherence, fungi penetrate the 
stratum corneum at a rate faster than desquamation (15, 16). Penetration is due to 
secretion of proteinases, lipases, and mucinolytic enzymes. Trauma and 
maceration also facilitate penetration (17-20). Defense mechanisms emerge once 
the deeper layers of epidermis are reached, like competition for iron by 
unsaturated transferrin and inhibition of fungal growth by progesterone 21. 
Degree of inflammation depends on system activation. 
Chemotaxis of inflammatory cells plays a major role. Fungi produce low-
molecular weight chemotactic factors like bacteria. Activation of complement 
also produces chemotactic factors. Keratinocytes induce chemotaxis by 
releasing IL-8.  Accumulating macrophages inhibit fungal growth by free 
radical nitric oxide. Fungal mannans inhibit inflammation and phagocytosis. 
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Skin contains antimicrobial peptides like human β-defensins, cathelicidin 
and dermicin. These peptides are active against bacteria, viruses and fungi 
22.Type IV, or delayed – type hypersensitivity (DTH), plays a major role in 
clearing dermatophytoses. This is due to interferon-gamma produced by type 1 
T-helper lymphocytes (TH1 cells). Primary infection cause minimal 
inflammation, and a trichophytin skin test in negative. The infection produces 
mild erythema and scale, due to increased keratinocyte turnover. Dermatophyte 
antigen is processed by Langerhans cells and presented in local lymph nodes to 
T lymphocytes (23-26). The T lymphocytes undergo clonal proliferation and 
migrate to the dermis and epidermis to attack the fungus. Lesion becomes 
inflammatory, and epidermal barrier becomes permeable to transferring and 
migrating cells. Soon the fungus is cleared and the lesion spontaneously 
resolves. The trichophytin skin test is now positive, and clearing of a second 
infection will be more rapid. Patients with IgE-mediated, immediate 
hypersensitivity (IH) reaction to the trichophytin skin test, are prone to chronic 
dermatophytoses, usually with T.rubrum23. 
             Dermatophytid reactions are inflammatory reactions of the skin at a site 
distant from the primary fungal infection. These are KOH examination and 
culture negative. Lesions are follicular papules, erythema nodosum, pityriasis 
rosea like, erythema multiforme like, vesicular id of the hands and feet, 
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erysipelas-like, erythema annular centrifugum, or urticaria. They disappear with 
resolution of the primary lesion. Intradermal test is positive.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
SUPERFICIAL CUTANEOUS MYCOSES:  
HISTORICAL ASPECTS: 
Study on superficial fungal infection started before 150 years.  Remak 
described the mycelia nature of favus. In 1841, Gruby isolated the organism of 
favus in culture and experimentally reproduced the disease with inoculation in 
normal skin. In 1910 Raymond Saboraud classified dermatophytes into four 
genera based on their microscopic and clinical characteristics. In 1934, 
Emmons’ described three genera - Epidermophyton, Microsporum, and 
Trichophyton. 
CLASSIFICATION: 
Very Superficial:  Pityriasis versicolor , Piedra and Tinea nigra 
Superficial: Dermatophytoses like Tinea corporis, Tinea cruris ,  
                   Tinea faciei, Tinea barbae , Tinea pedis and Candidiasis 
TINEA CORPORIS (TINEA CIRCINATA): 
Tinea corporis refers to all dermatophytoses of glabrous skin except the 
palms, soles, and groin. 
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EPIDEMIOLOGY: 
Tinea corporis is transmitted directly from infected humans or animals, 
via fomites, or via autoinoculation. Occlusive clothing, a warm humid climate, 
frequent skin-to-skin contact, and minor trauma are associated with more 
frequent and severe eruptions. There is a high prevalence of disease even in the 
absence of an epidemic. 
Tinea imbricata, caused by T.concentricum, is limited to areas of Far 
East, South Pacific, and South and Central Amercia. There is also genetic 
susceptibility27. 
CLINICAL MANIFESTATIONS: 
 The classic presentation is an annular lesion with well demarcated, raised 
and scaly erythematous border. The border is studded with vesicles and 
advances centrifugally. The center of the lesion shows clearing. Lesions are 
seen on exposed skin.  Immunosuppresion modifies the presentation. Presence 
of inflammatory changes is determined by the species and immunity of host.  
Pustules or vesicles can be seen in borders.  
Various presentations of Tinea corporis:  
 M.canis infections are characteristically annular. In T.verrucosum 
infections the characterisitic finding is annular lesion.  
12 
 
Various types of presentation due to T.rubum are extensive lesions28, 
psoriasiform and vasculitic lesions. Tokelau disease due to T.concentricum, is 
autosomal recessive in nature. The infection starts as a scaly ring with 
centrifungal spread, but later forms ring within ring pattern. Pruritus is intense 
and lead to lichenification. There is negative delayed hypersensitivity to 
T.concentricum cytoplasmic antigen, resolves with hypopigmentation (29, 30).  
Atypical forms of tinea corporis like extensive forms, subcutaneous 
nodules 31, and abscess occur. Rarely there is involvement of underlying 
structures like bone and lymph nodes. 
VARIANTS OF TINEA CORPORIS: 
Noninflammatory: 
• Tinea Circinata 
• Bullous tinea corporis 
• Tinea imbricata 
Inflammatory: 
• Kerion of glabrous skin Majocchi’s granuloma 
• Nodular granulomatous perifolliculitis of the legs 
• Agminate folliculitis 
• Subcutaneous abscess (tinea profunda) 
• Mycetoma 
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• Tinea faciale 
• Tinea incognito 
LABORATORY DIAGNOSIS: 
The most common diagnostic procedures are direct observation of fungi, culture 
and molecular diagnostic procedures.  
DIRECT MICROSCOPY:  
 Direct microscopy is done with the use of 10% potassium hydroxide. The 
scrapping materials are obtained from active margins with the help of 
disposable scalpel blade. If the scaling is minimal then scales are obtained with 
adhesive cello tape. If blisters are present the roof is nicked off and material is 
obtained. The scrapping material is transported in a black paper and mounted on 
a slide containing 10% KOH. The slide containing the scrapping material is 
warmed with Bunsen burner. The cover slip is pressed firmly. Excess KOH on 
slide is removed because it may damage the lens. Examination should be done 
under bright light illumination, but sometimes over illumination makes it 
difficult to diagnose the fungi. Other agents like 10% sodium sulphide and 35% 
dimethyl sulphoxide can be used. Other stains like Parker stain, congo red and 
methylene blue can be used to enhance the visibility of the fungus. The most 
recent method is Fluorescence microscopy using acridine orange which stains 
the polysaccharide present in fungal cell wall. The characteristic findings are 
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septate hyphae. They branch but do not constrict at the branching point (32-41).   
We should rule out mosaic fungus which is nothing but intercellular deposit of 
cholesterol which mimicks mycelium.  
HISTOPATHOLOGY: 
PAS stains of tinea circinata shows red hyphae within the stratum 
corneum – sandwich sign. Hyphae are basophilic with hematoxylin and eosin, 
and stain black with methenamine silver. If organisms are absent, the 
histopathology is nonspecific and resembles an acute or chronic dermatitis. The 
nodular perifolliculitis variant, caused by T.rubrum, shows a perifollicular 
granulomatous reaction accompanied by central necrosis and suppuration. 
Organisms are present in the hairs and dermis and large spore (6 um) may be 
found within multinucleated giant cells 42. 
CULTURE: 
Most of the superficial cutaneous mycoses do not require culture as mandatory 
because direct microscopy is sufficient to confirm diagnosis and start treatment. 
But certain infections like Tinea capitis and otomycosis require culture to 
identify the species because of the difference in response of various 
dermatophytes to antifungal. The most common culture medium used is 
Sabourauds dextrose agar. It contains 1% peptone and 2% sugar. Anti bacterials 
15 
 
like 0.005% chloramphenicol and 0.04% cycloheximide are added to inhibit the 
growth of bacteria and non dermatophytic moulds (2-10).  
MOLECULAR DIAGNOSTICS: 
Recently molecular diagnostic procedures like Polymerase chain reaction 
are used for the identification and classification of dermatophytes. The major 
advantage is that diagnosis can be achieved within a short period of 48 hrs. But 
the disadvantage is cost effectiveness (43-46).  
DIFFERENTIAL DIAGNOSIS: 
 Tinea corporis resembles many skin diseases, though diagnosis is usually 
straight forward. 
Seborrhoeic dermatitis is usually symmetrical lesions with greasy scales 
and is associated with seborrhoeic dermatitis of the scalp and other seborrhoeic 
areas. Psoriasis is characterized by erythematous raised scaly plaques on 
classical sites like elbows, knees and lumbosacral area with additional findings 
like pitting of nails. Impetigo often leads to confusion particularly of the 
circinate type. Lichenified lesions on leg resemble lichen simplex chronicus. 
Nummular eczema is characterized by symmetrical lesions on limbs. Pityriasis 
rosea especially Heralds patch is a close differential diagnosis since it occurs on 
trunk, but can be differentiated by fungal scrapping.  
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TOPICAL ANTIFUNGAL AGENTS 
 
 
 
 
 
 
 
 
Superficial fungal infections, including dermatophytoses are most often 
restricted to the epidermis. Factors guiding management include.  
• Extent and severity of the infection,  
• site of involvement 
• co-morbid conditions or potential drug interactions, if any, 
• anticipated efficacy of treatment 
• cost and access to medication, and  
• Ease of use. 
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Patients with limited fungal infections confined to glabrous skin are usually best 
treated with topical agents. Advantages of topical antifungals over systemic 
include: 
• less side effects 
• less drug interactions 
• localization of treatment  
• low cost 
Various topical antifungals are available. Non-specific topical treatments, 
like salicylic acid, gentian violet and Castellani’s paint which were once the 
mainstay of treatment are now replaced by specific antifungals.  
Classification of Topical antifungals:  
(1) imidazoles,  
(2) allylamines and benzylamines, and  
(3) polyenes and Miscellaneous 
(1) IMIDAZOLES 
Imidazoles are a broad group of antifungal medications. In this group 
certain medications like clotrimazole have been around for decades, while 
others like sertaconazole, are recently available. 
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MECHANISM OF ACTION: 
Imidazoles inhibit lanosterol 14a-demethylase, a cytochrome P dependent 
enzyme, which converts lanosterol to ergosterol. Depletion of ergosterol results 
in membrane instability and hyperpermeability, Imidazoles are fungistatic.  
Anti-inflammatory activity is through inhibition of neutrophil 
chemotaxis, calmodulin activity, synthesis of leukotrienes and prostaglandins, 
and histamine release from mast cells. Anti inflammatory effects of 
ketoconazole is equivalent to effect of 1% hydrocortisone. Imidazoles also 
possess limited antibacterial properties. 
PHARMACOKINETICS: 
 Imidazoles penetrate stratum corneum well due to keratinophilic nature.  
Sertaconazole has a half-life within the stratum corneum of more than 60 hours. 
Systemic absorption of imidazoles is low.  Urinary excretion is 0.3 % to 1.0 %. 
Even when applied to inflamed skin, absorption of imidazoles is only 4 % 47. 
INDICATIONS: 
Dermatophytosis,  
Candidiasis  
Seborrheic dermatitis 
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Erythrasma,impetigo and ecthyma.  
Topical imidazoles are available as a cream or lotion. Though lotions are 
suitable for large areas or hair-bearing skin , cream may be more effective48.  
DOSING REGIMEN: 
Econazole, ketoconazole, and oxiconazole are approved for once-daily 
dosing but twice-daily dosing is recommended for the remainder. Application 
should include normal skin radius of 2 cm beyond the lesion. Duration of 
treatment varies.  Tinea corporis and tinea cruris require treatment for 2 weeks; 
tinea pedis may require treatment for up to 4 weeks. Treatment should be 
continued for at least 1 week after all symptoms have resolved.  
RISKS AND PRECAUTIONS: 
Combination with the topical betamethasone dipropronate is more 
effective than clotrimazole alone in reducing symptoms. But after stopping the 
combination striae and other cutaneous side effects are reported.  High relapse 
rate has also been reported.  
COMPLICATIONS: 
Due to low systemic absorption, drug interactions with topical imidazoles 
are rare. However increased serum tacrolimus levels were reported in renal 
transplant recipients who used topical clotrimazole for mucocutaneous 
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candidiasis. Hence nystatin can be used in treating thrush in transplant patients 
using tacrolimus. 
Resistance of Candida albicans to clotrimazole is reported in HIV 
patients. 
SERTACONAZOLE NITRATE 2% CREAM: 
 
 
 
 
          Sertaconazole is an imidazole antifungal agent. Mode of action is 
inhibition of the synthesis of ergosterol, an essential cell wall component of 
fungi. Indications are treatment of superficial skin mycoses such as 
dermatophytosis (including tinea corporis, tinea cruris, tinea mannum, tinea 
barbae and tinea pedis), cutaneous candidiasis, pityriasis versicolor and 
seborrhoeic dermatitis of the scalp49. 
             Sertaconazole has broad-spectrum antifungal activity against 
Trichophyton, Epidermophyton and Microsporum genera, and yeasts of the 
genera Candida and Cryptococcus and also it is effective against opportunistic 
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filamentous fungi and Gram-positive bacteria. Though the drug has good dermal 
penetration, it is not associated with systemic absorption. 
 It is a potent fungicidal with antibacterial, antinflammatory properties 
with less relapse rate and beclamethasone is a chlorinated mid potent steroid 
with little systemic penetration. Combination of these two molecules may be 
more effective than existing therapies in relieving symptoms of erythema, 
scaling, pruritus, maceration and mycological cure rates. 
DRUG INTERACTIONS: 
Potential interactions between Sertaconazole nitrate Cream, 2% and other drugs 
are not yet established. 
STUDIES IN SPECIAL POPULATION: 
 Nursing Mothers:   Sertaconazole nitrate Cream, 2% secretion in human 
milk is unproved but since drugs are excreted in human milk, caution should be 
used while  prescribing Sertaconazole nitrate Cream, 2% to feeding women. 
 Pediatric Use: The efficacy and safety of Sertaconazole nitrate cream, 
2% in pediatric patients below the age of 12 years is not yet fully established 
ADVERSE REACTIONS: 
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 The reported cutaneous side effects are contact dermatitis, dry skin, burning 
skin, application site reaction and skin tenderness. 
LULICONAZOLE 1% CREAM: 
 
 
 
 
 Luliconazole is a recently developed imidazole . Mechanism of action is 
similar to other imidazoles in inhibiton of Lanosterol 14a – demethylase. It 
shows remarkable antifungal activity against dermatophytes. Luliconazole is 
also characterized in that its retention in the stratum corneum is extremely 
high50.  
 It demonstrates greater potency against Trichophyton spp. (MIC range : 
<0.00012-0.002 ug/ml) in particular T. rubrum . Luliconazole was also highly 
active against Candida albicans (MIC range: 0.031-0.13 ug/ml). Further the 
MIC of luliconazole against Malassezia restricta, and important pathogenic 
agent involved in seborrhoeic dermatitis is very low (MIC range: 0.004-0.016 
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ug/ml) suggesting action comparable to ketoconazole. Since there is no systemic 
absorption, adverse effects are rare.   
DRUG INTERACTIONS:  There are no reported interactions with other 
drugs. 
STUDIES IN SPECIAL POPULATION: 
 There are no reported adverse events in pregnant and lactating women. 
(2) ALLYLAMINES AND BENZYLAMINES 
Allylamines and benzylamines are closely related compounds. 
MECHANISM OF ACTION: 
Allyamines and benzylamines have similar action. They reduce synthesis 
of ergosterol by inhibition of squalene epoxidase. It is an enzyme which 
converts squalene to squalene epoxide. Reduced ergosterol results in membrane 
instability and hyperpermeability. They are fungicidal. Both are independent of 
cytochrome P enzyme system. 
They demonstrate anti-inflammatory activity by inhibition of chemotaxis, 
and inhibition of lipoxygenase. Allylamines and benzylamines show limited 
antibacterial properties51.  
PHARMACOKINETICS: 
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Allyamines and benzylamines are highly lipid soluble and penetrate the 
stratum corneum effectively and persist for longer duration. Butenafine persists 
in stratum corneum for at least 72 hours after application, and terbinafine 
persists for upto 7 days after application. Systemic absorption is quite low, with 
urinary excretion of 3 to 5 % of the applied dose 
INDICATIONS: 
Indications for the use of topical allylamines and topical benzylamines 
have been detailed. Despite antibacterial properties, terbinafine has proven 
inferior to mupirocin for treatment of impetigo, and a traditional antibacterial 
agent should be used instead. Similarly, although allylamines and benzylamines 
do demonstrate activity against dimorphic fungi involved in systemic infection 
such as Sporothrix schenckii, Blastomyces dermatitidis, and Histoplasmosis 
capsulatum, topical therapy is inappropriate in this situation. 
Limited evidence suggests that topical allylamines or benzylamines may 
be preferred over topical imidazoles for certain dermatophyte infections. 
Repeated trials for tinea pedis indicate that 1 week of topical terbinafine is as 
effective as 4 weeks of topical imidazoles, with cure resulting in 53 % to 95 % 
of cases. Use of this abbreviated treatment with terbinafine has been confirmed 
in trials using the active agent versus vehicle alone. In some instances, 
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resolution of tinea pedis using terbinafine as occurred with as few as three 
doses52. 
Currently a 30-g tube of terbinafine is three times more expensive than a 
30-g tube of clotrimazole. Considering the frequency of application, the amount 
of medication required the likelihood of patient compliance and ease of use, and 
the rapidity of results, some experts recommend topical terbinafine over topical 
imidazoles for tinea pedis. Nevertheless, using the same data, other experts have 
recommended initial use of less expensive imidazole therapy with reservation of 
allylamines and benzylamines for treatment failure. A consensus has not yet 
been achieved. 
Finally, topical allylamines and benzylamines are effective against 
candida or pityrosporum spp. However given the relative cost of these agents 
compared to cheaper, equally reliable, and specifically approved agents, such as 
imidazoles, polyenes, ciclopiroxolamine, and over-the counter selenium sulfide, 
there is no compelling reason to turn away from these more affordable options. 
DOSING REGIMEN:  
 Topical allylamines and benzylamines are available in a number of forms. 
Each agent has a slightly different dosing regimen based upon the formulation 
and the location and severity of infection. 
RISKS AND PRECAUTIONS: 
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Risks associated with use of topical allylamines and benzylamines are 
those inherent to all topical medicaments. 
TERBINAFINE 1% CREAM: 
 
 
 
 
 Terbinafine belongs to the allylamine class of antifungal agents. It 
inhibits squalene epoxidase, a membrane-bound enzyme. It is not part of the 
cytochrome P-450 superfamily. It is fungicidal to dermatophytes53-55. 
 Terbinafine exhibits fungicidal action against dermatophytes, Aspergillus 
species and dimorphic fungi. In vitro activity against yeasts has been weaker 
and varied. Terbinafine is fungicidal against C. parapsilosis but fungistatic 
against C. albicans54. 
 Terbinafine is well absorbed and highly lipophilic and keratophilic, and is 
distributed throughout adipose tissue, dermis, epidermis, and nails where it 
persists for weeks. It is delivered to the stratum corneum via the sebum and, to a 
lesser extent, through incorporation into the basal keratinocytes and diffusion 
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through the dermis-epidermis. Terbinafine is not found in eccrine sweat. 
Terbinafine is metabolized in the liver. In patients with renal disease, the 
elimination half-life can become prolonged. 
MAJOR DRUG INTERACTIONS: 
Concurrent use of terbinafine with caffeine, theophylline and napthylline may 
increase their toxicity; alcohol and hepatotoxic drugs may increase the risk of 
liver damage.  Drugs that induce the cytochrome P-450 system may increase the 
clearance of terbinafine and drugs that inhibit the cytochrome P-450 system 
may decrease the clearance of terbinafine. 
STUDIES IN SPECIAL POPULATION: 
 Children: There is limited experience with terbinafine in children 
ADVERSE REACTIONS: 
• Local cutaneous side effects like mild burning, irritation, and erythema. 
• Hypersensitivity reactions, including Stevens-Johnson syndrome and 
toxic epidermal necrolysis.  
• Gastrointestinal effects like nausea, dyspepsia, stomach pain, reversible 
loss of taste and hepatitis. 
• Hematologic effects like neutropenia and pancytopenia. 
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COMPLICATIONS: 
Complications occurring with use of topical allylamines or benzylamines 
are few. 
(3) POLYENES: 
Polyenes are the first to be discovered to possess specific antifungal 
properties. The two major topical polyene antifungals are nystatin and 
amphotericin B. Only topical nystatin is maximum available in market. 
MECHANISM OF ACTION: 
Nystatin binds irreversibly to membrance sterols and alters membrane 
permeability leading to leakage of essential intracellular components. Nystatin 
is fungistatic, but in high concentration it may be fungicidal. 
PHARMACOKINETICS: 
Nystatin is insoluble in water. It is not absorbed from intact skin, the 
gastrointestinal tract, or the vagina. 
INDICATIONS: 
Topical nystatin is used to treat mucocutaneous candidiasis. Since topical 
imidazoles are more effective than nystatin in treating vulvovaginal candidasis, 
use of nystatin has diminished in recent years. Nystatin is not effective against 
dermatophytes or pityrosporum. 
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DOSING REGIMEN: 
Nystatin is available as a powder, cream, ointment, suspension, and 
pastille. To treat oral candidiasis (thrush), the suspension is used four to five 
times daily, usually for 2 weeks. To treat cutaneous infection, the powder, 
cream, and ointment are used twice daily for approximately 2 weeks. 
RISKS AND PRECAUTIONS: 
Allergic contact dermatitis to nystatin has been reported with both topical 
and oral use. Analphylaxis has been reported but it is attributed to ingredients 
other than nystatin. 
Addition of triamcinolone may provide additional benefit during initial 
stages when inflammation is maximal. After this initial period, nystatin alone is 
used. Although triamcinolone acetonide is only a mid-potency agent, cutaneous 
sequelae, including striae, skin atrophy, and steroid-induced acne, has been 
reported.  
COMPLICATIONS: 
Complications are few. Nystatin resistance has been encountered.  
OTHER AGENTS: 
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Some topical antifungals, such as whitfield ointment, castellani paint, 
ciclpirox olamine, tolnaftate, and undecylenic acid, do not fit well into the major 
classes and are instead discussed separately. 
1. WHITFIELD OINTMENT: 
It is composed of 3% salicylic acid and 6% benzoic acid in ointment base. 
Salicylic acid acts as a keratolytic agent and and benzoic acid acts as fungicidal 
agent.   
2.  CASTELLANI OR PAINT OF MAGENTA: 
 Castellani′s paint is useful in management of tinea cruris and moniliasis 
of intertriginous areas, pustular dermatoses of the hands and feet, pruritusani 
and pruritus vulvae.  
COMPOSITION: 
 Basicfuchsin  
 Ethylalcohol  
 Boricacid 
 Phenol  
Acetone  
Resorcinol  
Water  
It is applied to affected areas at night with a cotton-tipped applicator and then 
dried and dusted with talc. 
3. CICLOPIROX OLAMINE: 
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Ciclopirox olamine is a hydroxypyridone antifungal agent with a unique 
structure and mode of action. 
MECHANISM OF ACTION: 
 Unlike most other topical antifungals, ciclopirox olamins does not 
interfere with sterol synthesis. Instead, it interrupts active membrance transport 
of essential cellular precursor’s particularly trivalent cations. Ultimately this 
disrupts cellular functions leading to death of the fungus. If concentrations of 
the drug are high enough the membrane integrity of the fungus may actually be 
impaired. 
Ciclopirox olamine also has inherent anti-inflammatory activity exerted 
through inhibition of prostaglandin and leukotriene synthesis within 
polymorphonuclear cells. Broad-spectrum antibacterial properties have also 
been attributed to ciclopriox olamine.  
PHARMACOKINETICS: 
When applied is the skin, ciclopirox olamine remains in high 
concentration within the epidermis and upper dermis. Ciclopirox olamine 
penetrates keratin easily. This ability to penetrate keratin recommends use for 
onychomycosis. Approximately 10 % of the administered dose is excreted in the 
urine. 
INDICATIONS: 
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Ciclopirox olamine is indicated for the treatment of dermatophytoses and 
onychomycosis, candidiasis, pityriasis versicolor, seborrheic dermatitis, and 
even cutaneous infections with unusual saprophytes. In tinea pedis, a mycologic 
cure rate of up to 85% has been observed, and in seborrheic dermatitis a 
significantly larger percentage of users had >75% improvement with 2 weeks of 
use than those using the shampoo vehicle alone. 
Although treatment with ciclopirox olamine for tinea pedis and 
seborrheic dermatitis has yielded results on par with other modalities, use in 
onychomycosis has met with more modest success. Often an assessment of 
efficacy depends upon whether a mycologic cure (culture negative) or clinical 
cure (a disease-free nail) defines success. Although a disease-free nail is often 
the patient’s true goal, ciclopirox olamine achieved such a response in just 5.5 
% to 8.56 % of those treated with a standard 48-week course. Two recent trails 
demonstrated increased efficacy when using oral terbinafine in combination 
with topical cicloprox olamine, as opposed to oral terbinafine alone. Debate 
regarding the use of ciclopirox olamine as an independent or adjunct treatment 
for onychomycosis is ongoing. 
DOSING REGIMEN: 
Circlopirox olamine is available in a wide range of forms. Cutaneous 
candidiasis, dermatophytoses, and pityriasis versicolor should be treated twice 
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daily for 2 weeks to 1 months, but treatment for tinea pedis should continue 1 
month or longer. While using ciclopirox shampoo for seborrheic dermatitis 
treatment done twice weekly for an indefinite duration. Improvement is 
generally noted in 2 to 4 weeks. Finally, in treating onychomycosis, the nail 
lacquer is applied daily to the nail and hyponychium for 48 weeks and excess 
medication is removed weekly with alcohol. 
RISKS AND PRECAUTIONS: 
Risks associated with use of topical ciclopirox olamine are those inherent 
to all topical medicaments. Allergic contact dermatitis has been reported only 
rarely, and ciclopirox olamine is considered a weak sensitizer. In patients with 
an allergic reaction to ciclopirox, imidazoles may be used with relative safety 
because of a markedly different chemical structure. 
COMPLICATIONS: 
Serious complications with topical ciclopirox olamine are few. 
OLDER AGENTS: 
Tolnaftate and undecylenic acid are older agents now available only in 
over-the-counter products. Repeated studies have now demonstrated that they 
are approximately equal in efficacy, and that both are less efficacious than 
topical imidazoles, allylamines, benzylamines, and ciclopirox olamine. 
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Additionally, tolnaftate is ineffective for treating candidiasis. Additionally 
topical forms of undecylenic acid may yield an unpleasant fishy smell that 
further discourages use. Because both agents are considered less efficacious 
than imidazoles, monitoring for treatment failure is indicated when using these 
medications. 
SYSTEMIC ANTIFUNGAL AGENTS: 
1.  GRISEOFULVIN: 
It is a heterocyclic benzofuran derived from penicillium griseofulvum .   
MECHANISM OF ACTION: 
Mode of action is inhibition of formation of intracellular microtubules which disrupts 
the mitotic spindle and prevents cell division of the fungus.  
PHARMACOKINETICS: 
Griseofulvin is poorly absorbed after oral administration because of its poor 
solubility in water hence it is advised to take along with a fatty meal and also in 
micronized form. 
The peak levels are achived in serum 4 hours after drug administration. 84% 
is bound to albumin and has low affinity for keratin. The drug is fungistatic and 
persists in the skin and nail for a very short time - 2 weeks after discontinuation of 
treatment.51 
It is predominantly metabolized in liver and excreted in urine. Its half life is 
9 to 22hrs.  
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INDICATIONS: 
Griseofulvin has a narrow spectrum of activity against dermatophytes only.56  
INTERACTIONS: 
Warfarin needs dosage adjustment. Dose of griseofulvin is to be 
increased while on barbiturates. It should not be administered during pregnancy 
because of the risk for developing conjoined twins.  
ADVERSE EFFECTS: 
Hypersensitivity, oral thrush, nausea, vomiting, epigastric distress, diarrhoea, 
headache, dizziness, insomnia, mental confusion, Liver failure, photosensitivity and 
precipitation of porphyria .  It is contraindicated in pregnancy as it causes conjoined 
twins 
Dose: 10 to 20 mg / kg Bw  
2. FLUCONAZOLE 
It is a triazole which inhibits the enzyme   lanosterol 14 alpha demethylase. 
The oral bioavailability is greater than 90%. The peak plasma concentration is 1to 2 
hours and half-life is 20 to 50 hours. 
Fluconazole has low lipophilicity and low level of plasma protein binding. It is 
excreted by renal system57.  
INDICATIONS: 
Fluconazole has proved safe and effective in the treatment of, 
dermatophytosis and fingernail and toe nail onychomycosis. 
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DOSE: 
150 mg, 300 mg or 450 mg once weekly for 9 - 12 months. 
INTERACTION: 
Cisapride, terfenadine, Cimeditine and rifampicin decreases plasma 
concentration of fluconazole. Hydrochlorothiazide increases plasma concentration 
of fluconazole. It increases plasma concentration of cyclosporin, astemizole, 
glipizide, phenytoin, rifabutin, tacrolimus . Prothrombin time is increased with 
anticoagulant.  
ADVERSE EFFECTS: 
Headache, skin rash, nausea, vomiting, diarrhoea, palpitations, sweating, 
fever. 
3.  ITRACONAZOLE 
It is a triazole derivative & disrupts the synthesis of ergosterol. 
It is highly lipophilic and oral bioavailability is maximum when taken with a 
full meal. Approximately 95% is bound to plasma albumin. It has a high affinity for 
keratinized tissues.  It persists for upto 6 months after discontinuation of therapy. 
Itraconazole is predominantly metabolised by the CYP 3A* iso-enzyme. 18% 
is excreted through feces and 40% of the dose is excreted as inactive metabolites in 
the urine58.  
INDICATIONS: 
Effective for dermatophytes, Candida and nondermatophyte moulds. 
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DRUG INTERACTIONS: 
Plasma concentration is decreased by carbamazepine, phenobarbitone, 
phenytoin, proton pump inhibitors and nevirapine. 
Plasma concentration is increased by erythromycin, clarithromycin, indinavir, 
ritonavir.  
ADVERSE EFFECTS: 
 Tremor, herpes zoster, abnormal dreaming, congestive heart failure and 
pulmonary edema have been reported.  
CONCLUSIONS: 
Because of relatively low cost, acceptable efficacy, ease of use and low 
potential for side effects, complications or drug interactions, topical antifungal 
are preferred for most superficial fungal infections of limited extent. 
Alternatively use of a systemic agent is justified when a superficial fungal 
infection covers a large surface area, involves terminal hair or nails, or has 
proven recalcitrant to prior topical management. Imidazoles provide a 
reasonable balance of efficacy and affordability and are indicated for treatment 
of dermatophytoses, mucocutaneous candidiasis, and pityrasis versicolor. 
Despite higher cost, allylamines and benzylamines may be advantageous in 
some cases of tinea pedis, due to shorter treatment courses. Cicloprix olamine is 
a topical antifungal with a unique mechanism of action and a broad range of 
indications. Topical nystation is useful in treating mucocutaneous candidiasis, 
38 
 
but is ineffective for dermatophyte infections. Use of tolnaftate and undecylenic 
acid is decreasing due to lower efficacy compared with other available agents. 
Localized tinea corporis, shows good response with topical therapy given 
twice daily. Topical terbinafine often works in a shorter time (e.g. 2 weeks). In 
extensive cases, systemic therapy is preferred for about 2-3 weeks. Griseofulvin, 
requires long-term treatment. Reinfection with T.concentricum is common in 
endemic area, as there is no long-lasting immunity. 
TREATMENT FAILURE 
Failure of topical therapy is due to faulty diagnosis, wrong use of topical 
therapy, or poor compliance.  
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To assess the efficacy of Sertaconazole nitrate 2 cream vs 
terbinafine 1% cream and luliconazole 1% cream in 
patients with  Superficial cutaneous mycoses ( Tinea 
corporis). 
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STUDY DESCRIPTION 
 Study design - Randomized, Prospective, open label, parallel group. 
 Study place - Dept of Dermatology, Govt. Stanley medical college & 
hospital,     Chennai 
 Source of patients - Patients attending Dermatology OPD and referred 
from other     Departments 
 Study period - August 2011 to December 2011 
 Duration – 5 months 
 Number of Patients – 90 
 Number of groups – 3 
Group A (n=30):  Sertaconazole nitrate 2% cream twice daily topical for 4 
weeks followed by 2 weeks observation for relapse. 
Group B (n=30): Terbinafine 1% cream once daily topical for 4 weeks 
followed by 2 weeks observation for relapse. 
Group C (n=30): Luliconazole 1% cream once daily topical for 4 weeks 
followed by 2 weeks observation for relapse. 
INCLUSION CRITERIA: 
41 
 
1. Male – 18 to 70 years. 
2. 
Female (post-menopausal, surgically sterilized or 
practicing a reliable method of birth control)  - 18 to 
70 years of age 
3. 
Tinea infections, confirmed by laboratory 
evaluation (microscopic examination confirmed by 
a positive potassium hydroxide (KOH) test) with 
inflammatory dermatoses. 
4. Written informed consent by patient. 
5. Patient willing to follow up. 
  
EXCLUSION CRITERIA: 
1. 
Though there are no proven contraindications, 
Pregnant and lactating women are excluded as a 
safety measure.  
2. 
Patients who took oral or topical treatment with 
antimycotics during the 4 weeks before trial 
3. 
Immunocompromised  (patients taking steroid, 
immunosuppresants or HIV/AIDS) 
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4. Associated bacterial infection. 
5. 
Hypersensitivity to Sertaconazole nitrate, 
beclomethasone dipropionate, miconazole or base of 
cream. 
6. 
Specific types of dermatophytoses like Majocchi 
granuloma which require systemic therapy 
 
SCREENING VISIT: 
 History of the patients will be noted. Patients will be assessed based on 
the inclusion and exclusion criteria. Written informed consent will be obtained. 
Clinical assessment of the condition will be carried. 
STUDY PLAN:  
 After screening, patients who fulfill inclusion criteria, willing to take part 
in trial and sign consent letters are advised to apply a thin film of study 
medication twice daily at morning and night on the affected area that has been 
cleansed and dried. One finger tip unit is applied in a circular fashion over 
affected area including surrounding normal skin.  Patients are advised to come 
for follow up on 7th, 14th, and 28th day & and follow-up visit on 42nd day of 
study medication for assessing the safety, efficacy and tolerability. Depending 
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on the response, study medication will be continued upto 4 weeks or stopped 
early after 2 weeks.  
CLINICAL EFFICACY PARAMETERS: 
 At each of the visits, clinical efficacy shall be assessed as follows: 
a) Clinical evaluation of the disease assessed in accordance with the efficacy 
parameters 
 
Visit I 
Baseline / 
Day 0) 
Visit II 
(Day 
7/Wk I) 
Visit III 
(Day 14/ 
Wk I1) 
Visit IV 
(Day 28/Wk 
IV 
Visit V 
(Day 42/ 
Wk VI 
Pruritus      
Erythema      
Desquamation      
 
Severity scale: worse-1, none or no improvement 0, Mild improvement 1, 
Moderate improvement 2 and clinical cure 3. 
b) Mycologic assessment for Tinea and Candida species (Based on KOH test) 
 
Note: + ve for KOH; -ve for KOH 
 
Visit I (Baseline 
/Day 0) 
Visit II (Day 
14/ Wk II) 
Visit III (Day 
28/Wk IV) 
Visit IV (Day 42 
/Wk VI) 
Mycologic 
assay 
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c) Physician Global assessment of clinical response scale: 
Tick the appropriate box () 
 
 
Visit I 
(Day 
14/ Wk 
II) 
 
Visit II     
(Day 
28/Wk 
IV) 
 
 
Visit III 
(Day 
42/Wk 
VI) 
 
Successful 
treatment 
outcome 
Effective clinical treatment – 
 Mycology –ve in addition to 
marked improvement over 
baseline signs and symptoms or 
 Clinical cure (mycology –ve in 
addition to normal appearance of 
skin) 
   
Clinical 
success 
Effective clinical treatment – 
 Marked improvement over 
pretreatment in signs and 
symptoms; at most,  mild 
residual erythema and /or scaling 
 Clinical cure (normal appearance 
of skin in all treated cutaneous 
dermatophytosis and or 
candidiasis completely resolved) 
   
Clinical 
failure 
Worsening of clinical status 
 Some pretreatment signs and 
symptoms of cutaneous 
dermatophytosis are more 
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severe or new symptoms are 
present 
 Mild clinical improvement or no 
change (pretreatment signs and 
symptoms have decreased or 
significant evidence of disease 
remains); or 
 Moderate clinical improvement 
(pretreatment signs and symptoms 
have  decreased ) 
 
Overall efficacy, safety and tolerability of Sertaconazole , Terbinafine and 
Luliconazole were assessed based on Quartile grading scale and Dermatology 
life quality index. 
QUARTILE GRADING SCALE: 
 Grade 1     -    <25%, minimal to no improvement 
 Grade 2     -      26–50%, moderate improvement 
 Grade 3     -      51–75%, marked improvement 
 Grade 4     -      75%, near total improvement 
DERMATOLOGY LIFE QUALITY INDEX : 
 0-1 = no effect at all on patient's life  
 2-5 = small effect on patient's life  
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 6-10 = moderate effect on patient's life  
 11-20 = very large effect on patient's life  
 21-31 = extremely large effect on patient's life 
INVESTIGATIONS: 
The following investigations will be done at the start of the study (screening 
visit)  and again repeated at the end of treatment period to assess tolerability of 
the study drug. 
• Hematology and Serum Biochemistry: 
 Haematology will include haemoglobin, total leucocyte count, 
differential  leucocyte count, total RBC count, platelet count & ESR. 
Biochemistry will include SGOT, SGPT and random blood sugar. 
• Urinalysis 
o Pregnancy tests in female patients in the reproductive age group. 
LABORATORY INVESTIGATIONS 
Parameters Screening Visit I Visit III or Visit IV 
Haemogram   
Hb gms/dl   
Total R.B.C/µl   
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Total W.B. C/µl   
Polymorphs%   
Lymphocytes%   
Monocytes %   
Basophils%   
ESR mm/hr   
Serum Biochemistry   
SGOT IU   
SGPT IU   
Fasting Blood glucose mg%   
Sr. Creatinine mg%   
Sr. BUN mg%   
 
• Urinalysis 
o Pregnancy tests in female patients in the reproductive age group. 
WITHDRAWAL OF PATIENTS IS DONE UNDER FOLLOWING 
CONDITIONS: 
1. Request of the patient. 
2. Repeated protocol criteria violation and non-compliance with its 
specification. 
3. Patient is lost to follow up 
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4. Serious adverse event/ reactions / intercurrent illness where continuation 
of study poses serious risk to the patient. 
5. Patients who develop signs & symptoms of hypersensitivity. 
6. Patients who become pregnant during the study period. 
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CLASSICAL TINEA CORPORIS 
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PSORIASIFORM TYPE 
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TINEA IMBRICATA 
 
 
 
 
 
 
 
52 
 
TINEA INCOGNITO 
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BEFORE TREATMENT 
 
 
 
 
 
 
 
 
 
Skin scrappings showing branching septate hyphae 
AFTER TREATMENT 
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BEFORE TREATMENT 
 
 
 
 
 
 
 
 
 
 
AFTER TREATMENT 
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BEFORE TREATMENT 
 
 
 
 
 
 
 
 
 
AFTER TREATMENT 
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TOPICAL SERTACONAZOLE 
BEFORE TREATMENT 
 
 
 
 
 
 
 
 
 
AFTER 4 WEEKS OF TREATMENT 
 
 
 
 
 
 
 
 
 
 
57 
 
TOICAL SERTACONAZOLE  
BEFORE TREATMENT 
 
 
 
 
 
 
AFTER  2 WEEKS OF TREATMENT 
 
 
 
 
 
 
AFTER 4 WEEKS OF TREATMENT 
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TOPICAL LULICONAZOLE 
BEFORE TREATMENT 
 
 
 
 
 
 
AFTER 2 WEEKS OF TREATMENT 
 
 
 
 
 
AFTER 4 WEEKS OF TREATMENT 
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TOPICAL LULICONAZOLE  
BEFORE TREATMENT 
 
 
 
 
 
 
 
 
 
AFTER 4 WEEKS OF TREATMENT 
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TOPICAL LULICONAZOLE 
BEFORE TREATMENT 
 
 
 
 
 
 
AFTER TREATMENT 
2 WEEKS      4 WEEKS 
 
 
 
 
 
 
 
 
AFTER  
6 WEEKS 
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TOPICAL TERBINAFINE  
BEFORE TREATMENT 
 
 
 
 
 
 
 
 
 
AFTER  2 WEEKS OF TREATMENT 
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TOPICAL TERBINAFINE 
BEFORE TREATMENT 
 
 
 
 
 
 
 
 
 
AFTER 4 WEEKS OF TREATMENT 
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TOPICAL TERBINAFINE 
BEFORE TREATMENT 
 
 
 
 
 
 
 
 
 
AFTER  2 WEEKS OF TREATMENT 
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TOPICAL TERBINAFINE 
BEFORE TREATMENT 
 
 
 
 
 
 
 
 
 
 
AFTER  2 WEEKS OF TREATMENT 
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The most common age group of involvement in our study was 30 – 40 
years. The average age of the patient in the study group is 35. 
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CLINICAL TYPES 
Type No. of Patients Percentage 
CLASSICAL – TINEA CIRCINATA 54 69.2 % 
TINEA IMBRICATA 5 6.4 % 
TINEA INCOGNITO 11 14.1 % 
PSORIASIFORM 6 7.69 % 
PERIFOLLICULAR 2 2.56 % 
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Classical Tinea corporis was the most frequent clinical pattern noted in 
54 patients followed by Tinea incognito in 11 patients, Psoriasiform in 6 
patients and Tinea imbricata type in 5 patients. Least common type was 
Perifollicular type noted in 2 patients. 
Of the 90 specimens studied, fungal elements were identified by positive 
KOH mounts in all specimens. 
During the course of the study, 12 patients were lost in follow up so they 
were excluded from final analysis. 
ASSOCIATED DERMATOLOGICAL CONDITIONS 
SNO DERMATOLOGICAL CONDITION NO OF PATIENTS 
1 Psoriasis 2 
2 Lichen planus 2 
3 Vitiligo 1 
4 Tinea versicolor 4 
5 Idiopathic guttate hypomelanosis 3 
6 Hansen 1 
7 Erythrasma 1 
8 Keratolysis punctata 2 
9 Intertrigo 1 
10 Perforating folliculitis 1 
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11 Lichen sclerosus atrophicus 1 
12 Pitting of nails 3 
13 Nevus achromicus 1 
 
MYCOLOGICAL RESPONSE IN THE STUDY GROUP 
GROUP TOTAL MYCOLOGICAL CURE PERCENTAGE 
A 25 11 44 
B 28 21 75 
C 25 14 56 
 
Mycological cure rate was 44%, 75%, 56% in Group A, B, C respectively. 
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CLINICAL RESPONSE IN THE STUDY GROUP 
Group Cured Total Percentage 
A 8 25 32 
B 21 28 75 
C 13 25 52 
 
Clinical cure was observed in 32%, 75% and 52% patients in group A, B, 
C respectively. 
No major adverse effect due to drug was observed in this study. 
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Red Marked values are P value 
Interpretation of P value 
If P value is 0.000 to 0.010 then denoted by **   => Significant at 1 % level 
If P value is 0.011 to 0.050 then denoted by *    => Significant at 5 % level 
If P value is above 0.05 => Not Significant at 5 % level 
If the P value is 0.000 it’s represented as <0.001** 
 
1. Group * Sex 
 
  Sex 
Total 
Male Female 
Group Group A Count 5 20 25 
% within Group 20.0% 80.0% 100.0% 
% within Sex 17.2% 40.8% 32.1% 
Group B Count 10 18 28 
% within Group 35.7% 64.3% 100.0% 
% within Sex 34.5% 36.7% 35.9% 
Group C Count 14 11 25 
% within Group 56.0% 44.0% 100.0% 
% within Sex 48.3% 22.4% 32.1% 
Total Count 29 49 78 
% within Group 37.2% 62.8% 100.0% 
% within Sex 100.0% 100.0% 100.0% 
 
 
Chi-Square Tests 
 
 Value df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 6.976(a) 2 .031 
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Group
Group CGroup BGroup A
C
ou
nt
30
20
10
0
Sex
Male
Female
Likelihood Ratio 7.130 2 .028 
Linear-by-Linear Association 6.847 1 .009 
No of Valid Cases 78   
 
 
A 0 cells (.0%) have expected count less than 5. The minimum expected 
count is 9.29. 
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2. Group * DM 
 
  
 
  
DM 
Total 
Positive Negative 
Group 
Group A 
Count 4 21 25 
% within Group 16.0% 84.0% 100.0% 
% within DM 23.5% 34.4% 32.1% 
Group B 
Count 8 20 28 
% within Group 28.6% 71.4% 100.0% 
% within DM 47.1% 32.8% 35.9% 
Group C 
Count 5 20 25 
% within Group 20.0% 80.0% 100.0% 
% within DM 29.4% 32.8% 32.1% 
Total 
Count 17 61 78 
% within Group 21.8% 78.2% 100.0% 
% within DM 100.0% 100.0% 100.0% 
 
 
 
Chi-Square Tests 
 
 Value df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 1.294(a) 2 .524 
Likelihood Ratio 1.284 2 .526 
Linear-by-Linear Association .116 1 .734 
No of Valid Cases 78   
 
 
A  0 cells (.0%) have expected count less than 5. The minimum expected 
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3. Group * Family history 
 
 
  
Family history 
Total 
Positive Negative 
Group 
Group A 
Count 2 23 25 
% within Group 8.0% 92.0% 100.0% 
% within Family history 66.7% 30.7% 32.1% 
Group B 
Count 0 28 28 
% within Group .0% 100.0% 100.0% 
% within Family history .0% 37.3% 35.9% 
Group C 
Count 1 24 25 
% within Group 4.0% 96.0% 100.0% 
% within Family history 33.3% 32.0% 32.1% 
Total 
Count 3 75 78 
% within Group 3.8% 96.2% 100.0% 
% within Family history 100.0% 100.0% 100.0% 
 
 
Chi-Square Tests 
 
  Value df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 
2.288(a) 2 .319 
Likelihood Ratio 
3.096 2 .213 
Linear-by-Linear Association 
.534 1 .465 
No of Valid Cases 
78   
 
A  3 cells (50.0%) have expected count less than 5. The minimum expected 
count is .96. 
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4. Group * Clinical type 
 
 
  Clinical type Total 
  
CLAS
SICAL 
PERI 
FOLLICU
LAR 
PERIFOLLI
CULAR 
PSORIASIF
ORM 
PSORISI
FORM 
TINEA 
IMBRI
CATA 
TINEA 
INCOGN
ITO 
 
Gro
up 
Gro
up 
A 
Count 17 0 1 2 0 3 2 25 
  
% within 
Group 
68.0% .0% 4.0% 8.0% .0% 12.0% 8.0% 100.0% 
  
% within 
Clinical 
type 
31.5% .0% 50.0% 33.3% .0% 60.0% 22.2% 32.1% 
 
Gro
up 
B 
Count 19 1 0 2 1 1 4 28 
  
% within 
Group 
67.9% 3.6% .0% 7.1% 3.6% 3.6% 14.3% 100.0% 
  
% within 
Clinical 
type 
35.2% 100.0% .0% 33.3% 100.0% 20.0% 44.4% 35.9% 
 
Gro
up 
C 
Count 18 0 1 2 0 1 3 25 
  
% within 
Group 
72.0% .0% 4.0% 8.0% .0% 4.0% 12.0% 100.0% 
  
% within 
Clinical 
type 
33.3% .0% 50.0% 33.3% .0% 20.0% 33.3% 32.1% 
Total Count 54 1 2 6 1 5 9 78 
 
% within 
Group 
69.2% 1.3% 2.6% 7.7% 1.3% 6.4% 11.5% 100.0% 
 
% within 
Clinical 
type 
100.0
% 
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
 
 
Chi-Square Tests 
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PERIFOLLICULAR
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 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 7.006(a) 12 .857 
Likelihood Ratio 8.063 12 .780 
No of Valid Cases 78   
 
A 18 cells (85.7%) have expected count less than 5. The minimum expected 
count is .32. 
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5. Mycological cure 
 
 
  
Mycological cure 
Total 
Positive Negative 
Group 
Group A 
Count 11 10 21 
% within Group 52.4% 47.6% 100.0% 
% within Mycological cure 23.9% 37.0% 28.8% 
Group B 
Count 21 7 28 
% within Group 75.0% 25.0% 100.0% 
% within Mycological cure 45.7% 25.9% 38.4% 
Group C 
Count 14 10 24 
% within Group 58.3% 41.7% 100.0% 
% within Mycological cure 30.4% 37.0% 32.9% 
Total 
Count 46 27 73 
% within Group 63.0% 37.0% 100.0% 
% within Mycological cure 100.0% 100.0% 100.0% 
 
 
Chi-Square Tests 
 
 Value df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 2.970(a) 2 .226 
Likelihood Ratio 3.040 2 .219 
Linear-by-Linear 
Association 
.116 1 .733 
No of Valid Cases 73   
 
A  0 cells (.0%) have expected count less than 5. The minimum expected 
count is 7.77. 
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6. Group * Clinical cure 
 
 
  
Clinical cure 
Total 
Positive Negative 
Group 
Group A 
Count 8 13 21 
% within Group 38.1% 61.9% 100.0% 
% within Clinical cure 19.0% 41.9% 28.8% 
Group B 
Count 21 7 28 
% within Group 75.0% 25.0% 100.0% 
% within Clinical cure 50.0% 22.6% 38.4% 
Group C 
Count 13 11 24 
% within Group 54.2% 45.8% 100.0% 
% within Clinical cure 31.0% 35.5% 32.9% 
Total 
Count 42 31 73 
% within Group 57.5% 42.5% 100.0% 
% within Clinical cure 100.0% 100.0% 100.0% 
 
 
Chi-Square Tests 
 
 Value df 
Asymp. Sig. 
 (2-sided) 
Pearson Chi-
Square 
6.855(a) 2 .032 
Likelihood Ratio 7.030 2 .030 
Linear-by-Linear 
Association 
.964 1 .326 
No of Valid Cases 73   
 
A  0 cells (.0%) have expected count less than 5. The minimum expected 
count is 8.92. 
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7. Group * Quartile grading 
 
 
    
Quartile grading 
Total 
1 2 3 4 
Group 
Group 
A 
Count 8 14 3 0 25 
% within Group 32.0% 56.0% 12.0% .0% 100.0%
% within Quartile 
grading 
80.0% 53.8% 11.1% .0% 32.1% 
Group B 
Count 0 3 12 13 28 
% within Group .0% 10.7% 42.9% 46.4% 100.0%
% within Quartile 
grading 
.0% 11.5% 44.4% 86.7% 35.9% 
Group C 
Count 2 9 12 2 25 
% within Group 8.0% 36.0% 48.0% 8.0% 100.0%
% within Quartile 
grading 
20.0% 34.6% 44.4% 13.3% 32.1% 
Total 
Count 10 26 27 15 78 
% within Group 12.8% 33.3% 34.6% 19.2% 100.0%
% within Quartile 
grading 
100.0% 100.0% 100.0% 100.0% 100.0%
 
Chi-Square Tests 
 
  Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 42.175(a) 6 .000 
Likelihood Ratio 47.874 6 .000 
Linear-by-Linear Association 8.095 1 .004 
No of Valid Cases 78     
 
A  5 cells (41.7%) have expected count less than 5. The minimum expected 
count is 3.21. 
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ANOVA TABLE: 
 
    Sum of Squares df 
Mean 
Square 
F Sig. 
Age in years Between Groups 34.748 2 17.374 .071 .932 
  Within Groups 18449.867 75 245.998     
  Total 18484.615 77       
Duration Between Groups 6.592 2 3.296 .781 .462 
  Within Groups 316.587 75 4.221     
  Total 323.179 77       
Quartile grading Between Groups 32.091 2 16.045 32.890 .000 
  Within Groups 36.589 75 .488     
  Total 68.679 77       
DLQI - before Between Groups 61.219 2 30.609 10.438 .000 
  Within Groups 205.274 70 2.932     
  Total 266.493 72       
DLQI - after Between Groups 41.886 2 20.943 15.363 .000 
  Within Groups 95.429 70 1.363     
  Total 137.315 72       
 
 
BASED ON THE P VALUE OF QUARTILE GRADING AND DLQI,  
THE STUDY CONDUCTED WAS SIGNIFICANT. 
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T-Test  
 
1. Paired Samples Statistics ( GROUP A) 
 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 
DLQI - before 6.36 25 1.705 .341 
DLQI - after 2.60 25 .707 .141 
 
 
Paired Samples Correlations 
 
 N Correlation Sig. 
Pair 1 DLQI - before & DLQI – after 25 .263 .205 
 
 
Paired Samples Test 
 
 
Paired Differences 
t df 
Sig.  
(2-
tailed)Mean 
Std. 
Deviation
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
DLQI - 
before 
DLQI - 
after 
3.76 1.665 .333 3.07 4.45 11.289 24 .000 
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T-Test  
2. Paired Samples Statistics (GROUP B) 
 
 
 
 
 
 
 
 
 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 
DLQI - before 6.96 28 1.666 .315 
DLQI - after 2.14 28 1.268 .240 
 
 
Paired Samples Correlations 
 
 N Correlation Sig. 
Pair 1 DLQI - before & DLQI – after 28 .335 .081 
 
 
Paired Samples Test 
 
 Paired Differences t df 
Sig. 
(2-
tailed) 
 Mean 
Std. 
Deviation
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
   
    Lower Upper    
Pair 
1 
DLQI - 
before - 
DLQI - 
after 
4.82 1.722 .326 4.15 5.49 14.812 27 .000 
 
 Mean SD 
DLQI - before 6.96 1.67 
DLQI - after 2.14 1.27 
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T-Test 
 
3. Paired Samples Statistics (GROUP C) 
 
 
 
 
 
 
 
 
 
 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 
DLQI - before 8.65 20 1.785 .399 
DLQI - after 4.00 20 1.451 .324 
 
 
Paired Samples Correlations 
 
 N Correlation Sig. 
Pair 1 DLQI - before & DLQI – after 20 .406 .075 
 
 
Paired Samples Test 
 
 
Paired Differences 
t df 
Sig. 
(2-
tailed) 
Mean 
Std. 
Deviation
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
DLQI - 
before - 
DLQI – 
after 
4.65 1.785 .399 3.81 5.49 11.649 19 .000 
 
 
 
 Mean SD 
DLQI - before 8.65 1.79
DLQI - after 4.00 1.45
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Tinea corporis can occur at any age but is most commonly seen during                    
adolescent and preadolescent 59. 
In our study the common age group affected was between 30   to 40 years 
compared to incidence in age group of 26 to 30 in a study conducted in chitwan 
district in Nepal 60. 
There is a slight male preponderance (56, 61) in cases of Tinea corporis but 
in our study incidence was more in females than males attributed due to higher 
number of female respondents in our study, due to increased contact of mothers 
with infected children, due to tight clothing and also due to females involved in 
some strenuous labour leading to increased sweating which is a predisposing 
factor. Similar female preponderance was reported in a study conducted in 
chitwan district in Nepal 60. The sex ratio is (1:1 for Group A; 1:4 for Group B, 
2:3 for Group C). 
Among the females the majority were housewives   
Diabetes mellitus was one of the predisposing factors in our study51.  
The other dermatological  conditions associated with Tinea corporis were 
Vitiligo, Psoriasis, Hansen’s,  Intertrigo, Keratolysis punctata, Erythrasma, 
Perforating folliculitis,  Lichen sclerosus et atrophicus, Tinea versicolor, 
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Idiopathic guttate hypomelanosis, nail pitting , Lichen planus  and Nevus 
achromicus. 
In this study, direct microscopic examination was positive in all the 
samples.  
Tinea corporis is known to be difficult to treat and often exerts a 
significant negative impact on the quality of life. The topical agents most 
commonly used for treatment of Tinea corporis are clotrimazole and other 
azoles, Terbinafine, nystatin, ciclopiroxolamine, amorolfine and other non 
specific measures like Whitfield ointment and castellani paint. 
The newer antifungal agents have better pharmacokinetic profiles such as 
persistence in the stratum corneum for several months even after the 
discontinuation of therapy and fewer adverse reactions. 
In our study terbinafine has high mycological cure rate with a statistically 
significant p value in efficacy than that of luliconazole and sertaconazole and 
ensuring that the patients are likely to complete the therapy compared to a study 
conducted in Jawahar lal Nehru medical college where sertaconazole was found 
to be as efficacious as terbinafine62. .Nearly 75% of patients showed both 
mycological and clinical cure completely compared to 92% in a study published 
in Paediatric infectious disease journal – june 1997 62. Adverse events with 
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terbinafine were very few. Only 1% of patients showed erythema, and only 2% 
felt burning sensation. Recurrence was seen only in 2% of patients.Most of the 
patients on Terbinafine showed faster mycological and clinical cure in 2 weeks 
compared to Sertaconazole and Luliconazole. Patients on sertaconazole and 
luliconazole showed recurrence.  
Future 
Terbinafine is an incredible topical anti fungal in the management of 
dermatophytosis and also onychomycosis. The use of topical Terbinafine is 
increasing every year.  Patients are showing great satisfaction with the use of 
Terbinafine. Terbinafine has been in use for the past 17 years. It has proved to 
be an extremely safe therapy for treatment of dermatophytosis.  
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9 Females are more commonly affected than males                      . 
9 Common age group is between 30 to 40 yrs. 
9 Diabetes was found to be a precipitating factor in few cases. 
9 Classical Tinea corporis is the commonest type. 
9 No specific systemic disease association in noted in this study. 
9 Therapeutic trial concludes that terbinafine is more efficacious, safe 
and tolerable than sertaconazole and luliconazole. 
9 Terbinafine is one of the most commonly used topical anti fungal in the 
treatment of dermatophytosis. 
9 It has a favourable mycological and pharmacokinetic profile. 
Advantages are 
9 Good penetration at the site of application 
9 Persistence in skin for longer durations 
9 Fungicidal activity 
9 Short course of treatment  
9 The efficacy, short duration, lesser side effects, cost effectiveness of 
the  Terbinafine  gives a positive approach in the treatment of 
Superficial cutaneous mycoses like Tinea corporis . 
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KEY TO MASTER CHART 
Sex 
M  -  Male 
F - Female 
Duration 
M - Months 
Wks - Weeks 
Past H/o 
HT -  Hypertension 
DM - Diabetes mellitus 
Other Association 
KP -  Keratolysis punctata 
TV - Tinea Versicolar 
IGH    -        Idiopathic guttate hypomelanosis 
LP      -        Lichen planus 
Lab Diagnosis 
KOH -  Potassium Hydroxide Examination 
+ - Positive 
- - Negative 
PROFORMA 
Serial Number 
Name Date 
Age  Address and contact number 
Sex 
Occupation 
Complaints: 
Duration 
Onset 
Site 
Associated Symptoms 
Precipitating factor 
H/o exposure to STD 
Past H/o  :  HT/DM/Peripheral vascular Disease/Varicose Veins/  
  Immunosuppressive therapy/ Atopic dermatitis. 
Family H/o  :  Other members affected or not. 
Personal H/o  :  Smoking / Alcoholic 
  Vegetarian / Mixed diet. 
Treatment H/o:   Topical    Topical 
Allopathic    Indigenous 
Systemic    Systemic 
General Examination: 
Anaemia / Pedal edema / Jaundice / Clubbing / Cyanosis / 
Generalized lymphadenopathy 
CVS PR 
RS BP 
Abdomen 
CNS 
Musculoskeletal System 
Skin: 
Types  :   
  Hair              : 
Mucosa  : 
Nail               : 
Others  : 
LAB INVESTIGATION  
Blood 
Hb% SGOT 
TC SGPT 
DC SAP 
ESR STP 
Platelet Count STB 
B.Sugar  KOH Mount 
B.Urea Culture 
S.Creatine Biopsy 
 
Urine 
Albumin 
Sugar 
Deposits 
 
RX GIVEN 
Topical  Systemic 
Response to therapy 
Follow up 
Remarks 
                                                           
 
 
 
 
CONSENT FORM 
Mr/Mrs/Miss: 
Age: 
Address: 
Phone: 
Name of the procedure: 
  I Undersigned Mr /Mrs /Miss                                                                                          
have been explained regarding above said procedure in my regional language. I am fully aware 
of the possible side effects and risks involved in this procedure. I am also aware that this 
procedure may not always be successful and no guarantee can be made for successful outcome of 
the procedure. 
 I have been explained that this procedure will be performed by Dr. M. Mani surya kumar. I have 
also been explained that during this procedure if any complication arises, I may be given any 
emergency treatment best suitable without asking my prior permission.  
I further state that I have carefully read and understood all the information provided in this form 
and with full conscious mind I hereby give my consent for the said procedure with its risks 
involved.  
Signature of the patient / Thumb impression: 
Signature of the parent / guardian (for minors): 
Name and relationship if signed by other than parent: 
Witness: 
Name:                                                                                           Signature: 
Date:                   
 
MASTER CHART – SERTACONAZOLE (GROUP A) 
 
 
NAME 
A
G
E/ 
SE
X 
OCCU
PATIO
N 
DUR
ATIO
N 
H
T 
D
M 
FA
MIL
Y 
HIS
TO
RY 
CLINIC
AL 
TYPE 
OTHE
RS 
LAB 
DIAG
NOSI
S 
MYCO
LOGIC
AL 
CURE 
CLI
NIC
AL 
CU
RE 
QUA
RTIL
E 
GRA
DIN
G 
DLQI  COMPLICATIONS 
BEF
OR
E 
AF
TE
R 
ERYT
HEM
A 
BUR
NIN
G 
RECU
RREN
CE 
SABARI
NATH 
47
/
M 
Mans
on  4 M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+ 
 
+  +  1  10  4  ‐  ‐  + 
RENUK
A 
23
/F 
House
wife  2M  +  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  ‐  ‐  1  9  4  ‐  ‐  ‐ 
MAHAL
AKSHM
I 
37
/F 
House
wife  6 M  ‐  ‐  ‐ 
CLASSIC
AL  KP 
KOH
+  +  +  2  5  3  ‐  ‐  ‐ 
SULOC
HANA 
42
/F 
House
wife  2 M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  ‐  1  4  3  ‐  +  ‐ 
SANDHI
YA 
30
/F 
House
wife  1 M  +  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  +  2  5  3  +  ‐  ‐ 
RICHAR
D 
42
/
M 
Manu
al 
labour
er 
1 M  ‐  ‐  +  CLASSICAL  TV 
KOH
+  ‐  ‐  2  5  3  ‐  ‐  + 
AYESHA  40/F 
House
wife  4 M  ‐  +  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  +  2  5  3  ‐  ‐  + 
RUBAN 
38
/
M 
Contr
actor  4 M  ‐  ‐  ‐ 
CLASSIC
AL 
ERYTH
RASM
A 
KOH
+  ‐  ‐  2  5  2  +  ‐  + 
BHARA
THI 
60
/F 
Water 
board 
worke
r 
4M  ‐  ‐  ‐ 
TINEA 
IMBRIC
ATA 
‐ 
KOH
+  +  +  2  7  2  +  ‐  ‐ 
ARPITH
A 
37
/F 
House
wife  1M  +  +  ‐ 
CLASSIC
AL  IGH 
KOH
+  ‐  ‐  3  8  2  ‐  ‐  ‐ 
RANJINI  40/F 
House
wife  4 M  ‐  ‐  ‐ 
PSORIAS
IFORM  ‐ 
KOH
+  +  ‐  1  7  1  ‐  ‐  ‐ 
RAMYA  40/F 
House
wife  3M  ‐  +  ‐ 
CLASSIC
AL  ‐ 
KOH
+  ‐  ‐  2  6  2  ‐  +  + 
LAVAN
YA 
26
/F 
House
wife  5M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  ‐  ‐  3  8  2  ‐  +  ‐ 
RAVI 
29
/
M 
House
wife  5M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  ‐  ‐  2  8  2  ‐  ‐  ‐ 
BALU 
15
/
M 
Stude
nt  1M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  ‐  ‐  2  8  3  ‐  +  + 
KUMAR
I 
28
/F 
House
wife  6 M  ‐  ‐  ‐ 
TINEA 
IMBRIC
ATA 
‐ 
KOH
+  ‐  +  2  8  3  ‐  ‐  + 
LEELA  30/F 
House
wife  3 M  +  ‐  ‐ 
TINEA 
IMBRIC
ATA 
‐ 
KOH
+  ‐  ‐  2  8  3  ‐  ‐  + 
DHANA
M 
58
/F 
Water 
Board 
worke
r 
6 M  ‐  ‐  ‐  PERIFOLLICULAR  IGH 
KOH
+  +  +  1  4  2  ‐  ‐  ‐ 
SUPRIY
A 
17
/F 
Bottle 
washe
r 
1 M  ‐  ‐  ‐  PSORIASIFORM  ‐ 
KOH
+  +  +  3  8  3  ‐  ‐  + 
PUSHP
AM 
36
/F 
Office 
Staff  2 M  ‐  ‐  + 
TINEA 
INCOGN
ITO 
Pitting  KOH+  ‐  ‐  2  6  3  ‐  ‐  + 
SRIVIDY
A 
38
/F 
House
wife  4 M  +  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  ‐  ‐  2  5  3  +  ‐  ‐ 
MANJU  44/F 
House
wife  3 M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  ‐  ‐  1  5  3  ‐  ‐  ‐ 
ASHWA
TH 
20
/F 
Sweep
er  6 M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  ‐  1  5  2  +  ‐  ‐ 
SUGUN
A 
70
/F 
House 
Wife  1M  ‐  +  ‐ 
CLASSIC
AL  TV 
KOH
+  ‐  ‐  1  5  2  ‐  ‐  ‐ 
MEERA  32/F 
House 
Wife  3 M  +  ‐  ‐ 
TINEA 
INCOGN
ITO 
‐ 
KOH
+  +  +  2  5  2  ‐  +  ‐ 
- 
 
 
 
 
 
 
 MASTER CHART – TERBINAFINE (GROUP B) 
 
NAME 
A
G
E 
/ 
SE
X 
OCCU
PATIO
N 
DUR
ATIO
N 
H
T 
D
M 
FA
MIL
Y 
HIS
TOR
Y 
CLINIC
AL 
TYPE 
OTH
ERS 
LAB 
DIAG
NOSI
S 
MYCO
LOGIC
AL 
CURE 
CLI
NIC
AL 
CUR
E 
QUA
RTIL
E 
GRA
DIN
G 
SCA
LE 
DLQI  COMPLICATION 
BEF
OR
E 
AF
TE
R 
ERYT
HEM
A 
BUR
NIN
G 
RECU
RREN
CE 
PAVITH
RA 
50
/F 
House 
Wife  1M  ‐  ‐  ‐ 
CLASSIC
AL 
Pitti
ng 
KOH
+  +  +  4  10  2  ‐  ‐  ‐ 
SRIRAM 
32
/
M 
Office 
Staff  2 M  ‐  +  ‐ 
TINEA 
IMBRIC
ATA 
Perf
orati
n 
diso
rder 
KOH
+  +  +  4  6  1  ‐  ‐  ‐ 
RAJA 
21
/
M 
Postal 
Staff  1M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  ‐  +  3  7  4  ‐  ‐  ‐ 
LAKSH
MI 
29
/F 
Juice 
Maker  1 M  +  +  ‐ 
CLASSIC
AL  ‐ 
KOH
+  ‐  +  3  8  2  ‐  ‐  ‐ 
MICHEA
L 
24
/
M 
Office 
Staff  2 M  ‐  ‐  ‐ 
CLASSIC
AL  TV 
KOH
+  +  +  3  9  3  ‐  ‐  ‐ 
RASHMI  43/F 
House 
Wife  3 M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  ‐  3  6  3  ‐  ‐  ‐ 
DEEPA  35/F 
House 
Wife  8 M  ‐  ‐  ‐ 
PSORISI
FORM  ‐ 
KOH
+  ‐  ‐  2  9  5  ‐  ‐  ‐ 
SUSANE  65/F 
House 
Wife  3 M  +  +  ‐ 
PSORIA
SIFORM  ‐ 
KOH
+  +  ‐  3  7  2  ‐  +  ‐ 
BHAVA
NA 
26
/F 
House 
Wife  2 M  ‐  ‐  ‐ 
TINEA 
INCOGN
ITO 
LSA  KOH+  +  ‐  3  8  2  ‐  ‐  ‐ 
SUSHM
A 
38
/F 
Rice 
mill 
labour
er 
4 M  ‐  ‐  ‐  CLASSICAL  ‐ 
KOH
+  +  +  4  7  1  +  ‐  + 
THULAS
I 
60
/F 
Farme
r  10 M  +  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  ‐  3  8  3  ‐  ‐  ‐ 
KARTHI
CK 
45
/
M 
Farme
r  8 M  ‐  ‐  ‐ 
CLASSIC
AL 
Han
sen’
s 
KOH
+  +  +  4  9  1  ‐  ‐  ‐ 
KAVITH
A 
25
/F 
House 
Wife  1 M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  +  4  6  2  ‐  ‐  ‐ 
SRIPAT
HY 
29
/
M 
Driver  2 M  ‐  ‐  ‐  CLASSICAL 
Psor
iasis 
KOH
+  ‐  ‐  2  8  5  ‐  ‐  ‐ 
MANIK
KAM 
18
/
M 
Stude
nt  3 M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  +  4  6  1  ‐  +  ‐ 
SAVITH
RI 
52
/F 
House 
Wife  3M  +  +  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  +  4  5  1  +  ‐  ‐ 
SORNA
KILI 
60
/F 
House 
Wife  2 M  ‐  +  ‐ 
CLASSIC
AL  LP 
KOH
+  +  +  4  4  1  ‐  ‐  + 
MEENA
KSHI 
55
/F 
Serva
nt 
maid 
2 M  ‐  ‐  ‐ 
TINEA 
INCOGN
ITO 
Inter
trigo 
KOH
+  ‐  +  3  3  1  ‐  ‐  ‐ 
FATHIM
A 
13
/F  ‐‐  7 M  ‐  ‐  ‐ 
PERI 
FOLLICU
LAR 
‐ 
KOH
+  ‐  +  3  6  2  ‐  ‐  ‐ 
DHIVYA  21/F 
House 
Wife  1 M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  +  4  5  0  ‐  ‐  ‐ 
ARUN 
22
/
M 
Stude
nt  2 M  ‐  ‐  ‐ 
CLASSIC
AL 
Pitti
ng 
KOH
+  ‐  ‐  2  5  4  ‐  ‐  ‐ 
LOKESH
WARAN 
32
/
M 
Welde
r  1 M  ‐  +  ‐ 
CLASSIC
AL  TV 
KOH
+  +  +  4  8  1  ‐  ‐  ‐ 
SURUSH 
32
/
M 
Chemi
st  3 M  ‐  ‐  ‐ 
TINEA 
INCOGN
ITO 
‐ 
KOH
+  +  +  4  7  1  +  +  ‐ 
GOWRI  55/F 
Farme
r  4 M  +  +  ‐ 
PSORIA
SIFORM  ‐ 
KOH
+  +  +  3  8  3  ‐  ‐‐  + 
SHANK
ARAN 
64
/F 
Watch
man  5 M  ‐  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  +  3  7  2  ‐  ‐  ‐ 
RAJESH 
30
/
M 
Medic
al 
Staff 
7 M  ‐  ‐  ‐  CLASSICAL  ‐ 
KOH
+  +  +  4  9  2  ‐  ‐  ‐ 
MARAD
ATHAM 
60
/F 
House 
Wife  4 M  +  ‐  ‐ 
CLASSIC
AL  ‐ 
KOH
+  +  +  4  8  2  ‐  ‐  ‐ 
THENM
OZHI 
65
/F 
Serva
nt 
Maid 
1 M  +  +  ‐ 
TINEA 
INCOGN
ITO 
‐ 
KOH
+  +  +  3  6  3  ‐  ‐  ‐ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART – LULICONAZOLE ( GROUP C ) 
 
NAME 
A
G
E 
/ 
S 
EX 
OCCU
PATIO
N 
DUR
ATIO
N 
H
T 
D
M 
FA
MIL
Y 
HIS
TO
RY 
CLINIC
AL 
TYPE 
OTH
ERS 
LAB 
DIAG
NOSI
S 
MYCO
LOGIC
AL 
CURE 
CLI
NIC
AL 
CUR
E 
QUA
RTIL
E 
GRA
DIN
G 
DLQI  COMPLICATION 
BEF
OR
E 
AF
TE
R 
ERYT
HEM
A 
BUR
NIN
G 
RECU
RREN
CE 
NAGAV
ALLI 
30
/F 
Farme
r 
1M  +  +  ‐ 
CLASSIC
AL 
Psori
asis 
KOH
+ 
+  +  4  10  2  ‐  ‐  ‐ 
PRAKAS
H 
44
/
M 
Farme
r 
2 M  +  ‐  ‐ 
TINEA 
IMBRIC
ATA 
LP 
KOH
+ 
+  +  3  11  6  ‐  ‐  ‐ 
KRISHN
AN 
28
/
M 
Merch
ant 
1 M  ‐  ‐  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
+  +  3  7  3  ‐  ‐  ‐ 
GOPAL 
67
/
M 
Hotel 
staff 
6 M  +  ‐  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
‐  ‐  3  8  4  ‐  ‐  ‐ 
KALKI 
25
/F 
House 
wife 
3 M  +  +  ‐ 
CLASSIC
AL 
Vitili
go 
KOH
+ 
‐  ‐  3  9  5  ‐  ‐  ‐ 
RADHA 
41
/F 
House 
wife 
1 M  ‐  ‐  ‐ 
CLASSIC
AL 
Kerat
olysi
s 
punc
tata 
KOH
+ 
‐  ‐  2  7  5  ‐  ‐  + 
ARUMU
GAN 
64
/
M 
Mans
on 
1 M  ‐  ‐  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
+  +  2  9  5  +  ‐  ‐ 
VINCEN
T 
32
/
M 
Electri
cian 
5 M  ‐  ‐  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
+  +  2  8  4  +  ‐  ‐ 
JAGDISH 
32
/
M 
Merch
ant 
5 M  ‐  ‐  ‐ 
PSORIAS
IFORM 
‐ 
KOH
+ 
‐  ‐  1  12  7  ‐‐  ‐  ‐ 
SMILEY 
30
/F 
Office 
staff 
5 M  ‐  +  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
‐  ‐  2  6  4  ‐  ‐  + 
TENNYS
ON 
42
/
M 
Driver  1 M  ‐  +  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
+  +  2  9  6  ‐  ‐  ‐ 
ANWAR 
21
/
M 
Office 
Staff 
2 M  ‐  ‐  ‐ 
CLASSIC
AL 
 
KOH
+ 
‐  ‐  3  10  4  ‐  ‐  ‐ 
PRAGAT
HI 
18
/F 
Stude
nt 
5 M  ‐  ‐  ‐ 
CLASSIC
AL 
Nevu
s 
achr
omic
us 
KOH
+ 
+  +  3  9  4  ‐  ‐  + 
RUKUM
ANI 
35
/F 
House 
Wife 
3 M  ‐  ‐  + 
CLASSIC
AL 
‐ 
KOH
+ 
+  +  3  6  2  +  ‐  + 
GLADI 
30
/F 
House
wife 
3 M  +  ‐  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
+  +  4  9  2  ‐  +  + 
MINTU 
49
/F 
House
wife 
1 M  ‐  ‐  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
+  +  3  12  3  ‐  ‐  ‐ 
SUDHAK
AR 
45
/
M 
Welde
r 
2 M  ‐  +  ‐ 
PERIFOL
LICULAR 
‐ 
KOH
+ 
+  +  3  6  2  ‐  ‐  ‐ 
KANDA
PPAN 
30
/
M 
LIC 
agent 
1 M  ‐  ‐  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
+  +  3  8  3  ‐  ‐  ‐ 
ANNAKI
LI 
29
/F 
House
wife 
2 M  ‐  ‐   
TINEA 
INCOGN
ITO 
IGH 
KOH
+ 
‐  ‐  2  9  4  ‐  ‐  ‐ 
PRABHA
KAR 
40
/
M 
Electri
cian 
6 M  ‐  ‐  ‐ 
TINEA 
INCOGN
ITO 
‐ 
KOH
+ 
‐  ‐  2  8  5  ‐  ‐  ‐ 
CHAND
RASEKA
R 
41
/
M 
Hotel 
Staff 
3 M  ‐  ‐  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
‐  ‐  1  7  4  ‐  ‐  + 
RAJU 
17
/
M 
Stude
nt 
1 M  ‐  ‐  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
‐  ‐  3  8  4  ‐  +  ‐ 
MANOH
ARI 
29
/F 
House
wife 
3 M  ‐  ‐  ‐ 
PSORIAS
IFORM 
‐ 
KOH
+ 
+  +  3  9  5  ‐  ‐  ‐ 
RAJESH
WARI 
26
/F 
House
wife 
1 M  ‐  ‐  ‐ 
TINEA 
INCOGN
ITO 
‐ 
KOH
+ 
+  ‐  2  9  5  +  ‐  ‐ 
UMA 
20
/F 
House
wife 
3 M  ‐  ‐  ‐ 
CLASSIC
AL 
‐ 
KOH
+ 
‐  ‐  2  8  5  ‐  ‐  + 
 
 
 
 
 
 
   
 
 
